King's College London

Research portal

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Article numbere1395127
Pages (from-to)e1395127-e1395127-11
Number of pages12
Issue number3
Early online date20 Nov 2017
Accepted/In press16 Oct 2017
E-pub ahead of print20 Nov 2017


  • Antibody structure and engineering_HOFFMAN_Publishedonline20November2017_GOLD VoR (CC BY)

    Hoffmann_et_al_OncoImmunology_ADC_2018.pdf, 1.08 MB, application/pdf

    Uploaded date:06 Feb 2018

    Version:Final published version

    Licence:CC BY

    This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

King's Authors


Antibody-drug conjugates (ADCs) are emerging as effective tools in cancer therapy, combining the antibody's exquisite specificity for the target antigen-expressing cancer cell together with the cytotoxic potency of the payload. Much success stems from the rational design of "toxic warheads", chemically linked to antibodies, and from fine-tuning the intricate properties of chemical linkers. Here, we focus on the antibody moiety of ADCs, dissecting the impact of Fab, linkers, isotype and Fc structure on the anti-tumoral and immune-activating functions of ADCs. Novel design approaches informed by antibody structural attributes present opportunities that may contribute to the success of next generation ADCs.

Download statistics

No data available

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454